Navigation Links
NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
Date:9/27/2007

ANN ARBOR, Mich., Sept. 27 /PRNewswire/ -- The National Institute of Standards and Technology (NIST) has selected Velcura Therapeutics, Inc. as an award winner in the Commerce Department's Advanced Technology Program (ATP), a peer-reviewed competition. NIST announced today that $2 million was awarded to the early-phase Michigan biotechnology company developing drug therapies to treat osteoporosis, bone cancer, bone fractures, and other bone disorders.

Velcura scientists have discovered a family of small molecules that possess characteristics of dual-action therapies, both stimulating bone formation and inhibiting loss. "These molecules are rapidly cleared from the blood stream, so these new drugs offer low systemic exposure, reduced off- target effects and extended time on target resulting in increased efficacy," according to Michael W. Long, PhD, president and CEO of Velcura Therapeutics, Inc. "This makes them effective agents for cancer patients and Velcura will start clinical trials I Multiple Myeloma patients for its first therapy, VEL- 0230, in early 2008."

Velcura's ATP funding supports the development of improved, or second- generation, molecules for use in bone diseases requiring long-term therapy, such rheumatoid arthritis or osteoporosis. "Velcura will use the ATP funding to invent new types of therapeutic molecules that retain the advantages of the current generation of compounds and their dual-action effects," Dr. Long added.

The ATP choose Velcura for its innovative approaches both at the level of medicinal chemistry and in the area of bone cell assay development. Velcura's new therapy could have a major economic impact on the treatment of many bone diseases such as osteoporosis that affects more than 10 million Americans. Current projections indicate a more than $60 billion market worldwide for diagnosis and treatment of the bone disease by 2020.

About Velcura Therapeutics(R), Inc.

Velcura Therapeutics Inc. is an early stage biotechnology company headquartered in Ann Arbor, Michigan. Velcura's research focus is to better understand human bone disease and to discover novel therapeutics that restore bone health. Velcura develops highly differentiated therapies for bone disease; specifically, dual-acting therapies that demonstrate both anabolic bone-building and anti-bone-loss activities in a single molecule. Velcura uses its patented platform technologies to discover and optimize compounds that both simulate and inhibit bone growth. Velcura's lead compound, VEL-0230 was identified using these bone assays. More information is at http://www.velcura.com.

About the Advanced Technology Program

Managed by the National Institute of Standards and Technology (NIST), the Advanced Technology Program encourages research on technologies that lead to revolutionary new products and industrial processes and services that address national priorities and generate large societal benefits. Winners are chosen on scientific and technological merit and potential for broad-based economic benefits. A single company can receive up to a total of $2 million for research and development activities for up to three years. Information on the 2007 Advanced Technology Program competition is available at http://www.atp.nist.gov/ and http://www.nist.gov/public_affairs/releases/atp_2007_awards.html. Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Michael W. Long, Ph.D. http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=49215


'/>"/>
SOURCE Velcura Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Pelosi: Bush Veto of Stem Cell Bill Says No to the Hopes of Million of Families Across America
2. Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million Annually
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
5. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
6. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
7. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
8. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
9. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
10. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
11. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)...  South Korean-based healthcare product Development Company I.M. Lab ... Kickstarter. The device will educate the user about ,proper, ... efficiency compared to the dated and pricey CPR training ... of the compression for a more informed CPR training. ... raise $5,000. cprCUBE ...
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations ... literacy software tool, and the Cancer Patient Education Network (CPEN), an independent professional ... announce a new strategic alliance. , As CPEN’s strategic partner, HLI will ...
Breaking Medicine News(10 mins):